Tag: SOHO-02
-
Bayer’s Hyrnuo Wins First-Line FDA Approval in HER2-Mutant Lung Cancer
The FDA granted Bayer’s Hyrnuo accelerated approval as a first-line treatment for HER2-mutant non-small cell lung cancer after the oral therapy achieved a 75% response rate in SOHO-01.